Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2014

View Archived Issues

FDA grants triheptanoin orphan drug status for GLUT-1 deficiency syndrome

Researchers use germline DNA gene editing to prevent muscular dystrophy in mice

Development of a receptor tyrosine kinase decoy as a potential anticancer therapy

Clenbuterol earns FDA orphan drug designation as adjunctive therapy for Pompe's disease

Papillary thyroid carcinoma predisposition linked to a mutation in the SRRM2 gene

IL28B gene polymorphisms examined in chronic hepatitis B

Triphase expands collaboration with Celgene

Ventana Medical Systems to develop companion diagnostics for ImmunoGen

New gene linked to Charcot-Marie-Tooth disease

Novartis reflects on accomplishments of third quarter 2014

Bristol-Myers Squibb reports new HIV integrase inhibitors

PATH reports on phase I/IIb study of ACE-527 ETEC vaccine

Osteros Biomedica begins phase I trial of MBC-11

Shire reports pipeline progress of third quarter 2014

Saniona acquires obesity candidate from NeuroSearch

Cara Therapeutics reports data from CR-845 trial

Dr. Falk Pharma enrolls first patients in phase III trial of LT-02

FDA grants accelerated approval to Trumenba for prevention of meningococcal meningitis B

FDA approves Xigduo XR for type 2 diabetes

FDA grants fast track designation to Novavax's H7N9 VLP vaccine candidate

Alkem and Georgetown University patent Flavivirus protease inhibitors

New LpxC inhibitors reported by Achaogen

GW Pharmaceuticals initiates phase II/III study of Epidiolex for Dravet syndrome

Roche patents new BTK inhibitors

Quanticel Pharmaceuticals presents new histone demethylase inhibitors

Imago Biosciences reports new KDM1A inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...